Pipeline

There is still much to learn about ALS, and R&D is a critical pillar of how we’ll deliver on our mission to one day end the suffering caused by neurodegenerative diseases.

Learn more about our commitment to research in ALS: amylyx.com/ALS

Progressive supranuclear palsy (PSP) is a rare, progressive, and adult-onset neurological disorder that affects walking and balance, eye movement, swallowing, and speech. People living with PSP have a life expectancy of six to eight years after initial diagnosis, and the epidemiology of PSP is similar to that of ALS. PSP is characterized by abnormal tau inclusions and is consequently also known as a tauopathy.

Learn more about our research in PSP: amylyx.com/PSP

Wolfram syndrome (WS) is an autosomal recessive neurodegenerative disease characterized by juvenile onset diabetes mellitus, optic nerve atrophy, deafness, and diabetes insipdius. WS is considered a prototypical endoplasmic reticulum (ER) stress disorder. The prognosis of WS is poor, and many people with the disease die prematurely with severe neurological disabilities.

Alzheimer’s Disease is a relentlessly progressive disease affecting the memories, thoughts and behavior of millions of people worldwide. Through our research, we aim to further characterize the biological activity of our candidates to inform potential clinical development.